Molecular changes in androgen-independent prostate cancer
Public access within GeneSifter
[
]
If you don't have the username and password, please register
here.
Microarray Platform: Affymetrix GeneChip Human Genome U133A Array
Reference: Data available from Gene Expression Omnibus (GEO),
GSE2443 dataset.
Best C.J., Gillespie J.W., Yi Y., Chandramouli G.V., Perlmutter M.A., Gathright Y., Erickson H.S., Georgevich L., Tangrea M.A., Duray P.H., Gonzalez S., Velasco A., Linehan W.M., Matusik R.J., Price D.K., Figg W.D., Emmert-Buck M.R., Chuaqui R.F. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6823-34.
Abstract:
Many prostate carcinomas are initially responsive to androgen-ablation therapy. However, resistance to this initial androgen blockade usually develops, and correlates with progression to androgen-independent disease. We used publicly available microarray data to examine the molecular changes between androgen-dependent and -independent primary prostate tumors. The data was generated by a study examining gene expression changes in prostate cancer after androgen ablation therapy (Best, et al., 2005), and subsequently analyzed with GeneSifter microarray analysis software (VizX Labs, Seattle, WA). This analysis system was used to discover differentially regulated genes, and map them to candidate gene ontology terms and pathways. Several clear patterns of gene expression were discovered which correlated with genes involved in RNA metabolism, cell cycle, macromolecular biosynthesis, and apoptosis.
